Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ArriVent BioPharma, Inc. (AVBP)
USD32.77
+0.23 (+0.71%)
US NASDAQ Healthcare Biotechnology
Address
18 Campus Boulevard Suite 100 19073
Newtown Square, PA, US
Newtown Square, PA, US
CEO
Zhengbin Yao
Website
arrivent.com
IPO
2024-01-26
CIK 1868279 ISIN US04272N1028
Description
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD32.77
+0.23 (+0.71%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
548.0K
Beta
1.30
Float Shares
31.38M
Free Float %
67.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.17% | -2.10% | +13.79% | +29.21% | +43.42% | +43.99% | +44.92% | +44.85% | +44.85% | +44.85% | +44.85% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
32.77
Low
43.00
+31.2%
Consensus
44.00
+34.3%
Median
44.00
+34.3%
High
45.00
+37.3%
DCF (Unlevered)
1.04
-96.8%
DCF (Levered)
1.18
-96.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 12 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 3 |
40.33
+23.1%
|
| All Time | 7 |
36.86
+12.5%
|
Quality scores
Altman Z-Score
30.22
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-68.8% Q1'26: +49.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+22.2% Q1'26: +32.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00×
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 9 EPS Ana. |
Dec 2027 6 Rev. Ana. 6 EPS Ana. |
Dec 2028 8 Rev. Ana. 6 EPS Ana. |
Dec 2029 7 Rev. Ana. 4 EPS Ana. |
Dec 2030 7 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: -1.67M (+100.0%)
|
—
est: 3.00M (-100.0%)
|
—
est: 5.50M (-100.0%)
|
125.0K
75.2K – 174.8K
-97.7% YoY
|
39.67M
34.60M – 44.74M
+31,636.1% YoY
|
140.39M
137.25M – 143.52M
+253.9% YoY
|
266.77M
160.60M – 373.06M
+90.0% YoY
|
433.92M
261.21M – 606.79M
+62.7% YoY
|
| EBITDA |
-74.59M
|
-80.49M
|
-177.53M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-74.59M
|
-80.49M
|
-177.53M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-69.33M
est: -268.77M (+74.2%)
|
-80.49M
est: -100.88M (+20.2%)
|
-166.31M
est: -169.43M (+1.8%)
|
-143.53M
-162.16M – -124.90M
+15.3% YoY
|
-123.11M
-126.60M – -119.61M
+14.2% YoY
|
-84.16M
-127.35M – 67.27M
+31.6% YoY
|
22.69M
10.95M – 34.45M
+127.0% YoY
|
124.88M
60.26M – 189.55M
+450.3% YoY
|
| SGA |
9.71M
|
15.30M
|
24.18M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-2.17
est: -8.54 (+74.6%)
|
-2.56
est: -2.58 (+0.8%)
|
-4.32
est: -4.41 (+2.0%)
|
-3.83
-4.22 – -3.25
+13.1% YoY
|
-3.21
-3.29 – -3.11
+16.4% YoY
|
-1.38
-3.31 – 1.75
+56.9% YoY
|
0.59
0.28 – 0.90
+142.7% YoY
|
3.25
1.57 – 4.93
+450.3% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-24 | Citigroup | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
33
Total invested
25.58M
Insider transactions (90d)
0
Beneficial owners (>5%)
23
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HHLR Advisors, Ltd. | 4.48M | 13.40% | — | 4.48M | — | — | IA | Cayman Islands | 2024-11-14 | ↗ |
| 2 | Hillhouse Investment Management, Ltd. | 4.48M | 13.40% | — | 4.48M | — | — | IA | Cayman Islands | 2024-11-14 | ↗ |
| 3 | Abigail P. Johnson | 2.12M | 6.31% | — | — | 2.12M | — | IN | Delaware | 2024-11-12 | ↗ |
| 4 | FMR LLC | 2.12M | 6.31% | 2.12M | — | 2.12M | — | HC | Delaware | 2024-11-12 | ↗ |
| 5 | Yi Shi | 2.05M | 6.40% | — | 2.05M | — | 2.05M | IN | United States | 2024-02-13 | ↗ |
| 6 | Aaron Cowen | 2.04M | 6.10% | — | 2.04M | — | 2.04M | HC, IN | Delaware | 2024-12-04 | ↗ |
| 7 | Suvretta Capital Management, LLC | 2.04M | 6.10% | — | 2.04M | — | 2.04M | IA, OO | Delaware | 2024-12-04 | ↗ |
| 8 | Ting Jia | 1.98M | 5.90% | — | 1.98M | — | 1.98M | HC, IN | Delaware | 2024-10-11 | ↗ |
| 9 | LAV Fund VI, L.P. (“LAVVI”) | 1.97M | 6.20% | — | 1.97M | — | 1.97M | PN | Cayman Islands | 2024-02-13 | ↗ |
| 10 | (1) BlackRock, Inc. | 1.93M | 5.80% | 1.91M | — | 1.93M | — | HC | Delaware | 2024-11-08 | ↗ |
| 11 | Averill Master Fund, Ltd. | 1.82M | 5.40% | — | 1.82M | — | 1.82M | CO | Delaware | 2024-12-04 | ↗ |
| 12 | Dr. James I. Healy (“Healy”) | 1.70M | 5.10% | — | 1.70M | — | 1.70M | IN | Delaware | 2024-11-12 | ↗ |
| 13 | Dr. Maha Katabi (“Katabi”) | 1.70M | 5.10% | — | 1.70M | — | 1.70M | IN | Delaware | 2024-11-12 | ↗ |
| 14 | Sofinnova Management XI, L.L.C. (“SM XI LLC”) | 1.70M | 5.10% | 1.70M | — | 1.70M | — | OO | Delaware | 2024-11-12 | ↗ |
| 15 | Sofinnova Management XI, L.P. (“SM XI LP”) | 1.70M | 5.10% | 1.70M | — | 1.70M | — | PN | Delaware | 2024-11-12 | ↗ |
| 16 | Sofinnova Venture Partners XI, L.P. (“SVP XI”) | 1.70M | 5.10% | 1.70M | — | 1.70M | — | PN | Delaware | 2024-11-12 | ↗ |
| 17 | Octagon Private Opportunities Fund LP | 799.9K | 2.40% | — | 799.9K | — | 799.9K | PN, OO | Delaware | 2024-10-11 | ↗ |
| 18 | Octagon Investments Master Fund LP | 782.0K | 2.30% | — | 782.0K | — | 782.0K | PN, OO | Delaware | 2024-10-11 | ↗ |
| 19 | Octagon Special Opportunities Fund LP – Series 4 | 394.5K | 1.20% | — | 394.5K | — | 394.5K | PN, OO | Delaware | 2024-10-11 | ↗ |
| 20 | LAV Star Limited (“STAR”) | 40.0K | 0.10% | — | 40.0K | — | 40.0K | OO | Virgin Islands | 2024-02-13 | ↗ |
| 21 | Opportunities”) | 40.0K | 0.10% | — | 40.0K | — | 40.0K | OO | Virgin Islands | 2024-02-13 | ↗ |
| 22 | Octagon Capital Advisors LP | 2.0K | 5.90% | — | 2.0K | — | 2.0K | IA, PN | Delaware | 2024-10-11 | ↗ |
| 23 | SCHEDULE 13D | 12.00 | 14.00% | — | 3.03M | — | 3.03M | IA | — | 2024-02-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
33
-88 vs prev Q
New positions
5
Closed positions
93
Increased
21
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 644.8K +644.8K (+100.0%) | 12.97B +13.0B (+100.0%) | 1.54% +1.538 pp | 12.16% +12.157 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 2 | INFINITUM ASSET MANAGEMENT, LLC | 4.12M +255.0K (+6.6%) | 82.97M +11.6M (+16.2%) | 9.84% +0.608 pp | 12.28% -0.848 pp | USD22.91 -12.2% | 5 qtrs — |
| 3 | SUVRETTA CAPITAL MANAGEMENT, LLC | 4.11M +402.6K (+10.9%) | 82.61M +14.3M (+20.9%) | 9.80% +0.961 pp | 1.69% -0.057 pp | USD20.38 -1.3% | 8 qtrs — |
| 4 | HHLR ADVISORS, LTD. | 3.93M -555.6K (-12.4%) | 79.05M -3.7M (-4.5%) | 9.37% -1.326 pp | 2.55% +0.524 pp | USD18.29 +10.0% | 8 qtrs — |
| 5 | FMR LLC | 3.70M +296.0K (+8.7%) | 74.52M +11.6M (+18.5%) | 8.84% +0.706 pp | 0.00% +0.001 pp | USD18.74 +7.4% | 8 qtrs — |
| 6 | ORBIMED ADVISORS LLC | 3.03M +— (+0.0%) | 60.91M +5.1M (+9.1%) | 7.22% +0.000 pp | 1.25% -0.068 pp | USD18.31 +9.9% | 8 qtrs — |
| 7 | BLACKROCK, INC. | 2.37M +326.7K (+16.0%) | 47.74M +10.0M (+26.5%) | 5.66% +0.780 pp | 0.00% +0.000 pp | USD22.82 -11.8% | 6 qtrs — |
| 8 | OCTAGON CAPITAL ADVISORS LP | 1.97M +— (+0.0%) | 39.66M +3.3M (+9.1%) | 4.70% +0.000 pp | 4.81% -0.697 pp | USD19.07 +5.5% | 8 qtrs — |
| 9 | NOVO HOLDINGS A/S | 1.94M +— (+0.0%) | 39.08M +3.2M (+9.1%) | 4.63% +0.000 pp | 3.03% +0.725 pp | USD18.39 +9.4% | 8 qtrs — |
| 10 | VANGUARD GROUP INC | 1.87M -160.3K (-7.9%) | 37.61M +164.8K (+0.4%) | 4.46% -0.382 pp | 0.00% +0.000 pp | USD20.40 -1.4% | 8 qtrs — |
| 11 | SOFINNOVA INVESTMENTS, INC. | 1.70M +— (+0.0%) | 34.14M +2.8M (+9.1%) | 4.05% +0.000 pp | 1.47% -0.240 pp | USD18.31 +9.9% | 8 qtrs — |
| 12 | GENERAL CATALYST GROUP MANAGEMENT, LLC | 1.49M +— (+0.0%) | 30.08M +2.5M (+9.1%) | 3.57% +0.000 pp | 13.56% +12.656 pp | USD18.31 +9.9% | 8 qtrs — |
| 13 | STATE STREET CORP | 1.09M +64.4K (+6.3%) | 21.97M +3.0M (+15.9%) | 2.61% +0.154 pp | 0.00% +0.000 pp | USD22.19 -9.3% | 8 qtrs — |
| 14 | SC CHINA HOLDING LTD | 663.3K +— (+0.0%) | 16.72M +3.7M (+28.6%) | 1.58% +0.000 pp | 0.88% +0.207 pp | USD18.31 +9.9% | 8 qtrs — |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 753.5K +37.2K (+5.2%) | 15.16M +1.9M (+14.7%) | 1.80% +0.089 pp | 0.00% +0.000 pp | USD20.84 -3.5% | 8 qtrs — |
| 16 | GOLDMAN SACHS GROUP INC | 742.5K +310.6K (+71.9%) | 14.94M +7.0M (+87.5%) | 1.77% +0.741 pp | 0.00% +0.001 pp | USD21.05 -4.4% | 6 qtrs — |
| 17 | FUND 1 INVESTMENTS, LLC | 565.9K -54.0K (-8.7%) | 11.38M -51.3K (-0.4%) | 1.35% -0.129 pp | 1.39% +0.122 pp | USD21.28 -5.5% | 3 qtrs — |
| 18 | CITADEL ADVISORS LLC | 458.5K +458.5K (+100.0%) | 9.23M +9.2M (+100.0%) | 1.09% +1.094 pp | 0.00% +0.001 pp | USD20.12 +0.0% | 3 qtrs — |
| 19 | UBS GROUP AG | 450.9K -46.7K (-9.4%) | 9.07M -108.2K (-1.2%) | 1.08% -0.111 pp | 0.00% +0.000 pp | USD18.86 +6.7% | 8 qtrs — |
| 20 | MILLENNIUM MANAGEMENT LLC | 282.0K -4.2K (-1.5%) | 5.67M +394.3K (+7.5%) | 0.67% -0.010 pp | 0.00% +0.000 pp | USD19.55 +2.9% | 8 qtrs — |
| 21 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 250.6K +7.1K (+2.9%) | 5.04M +549.5K (+12.2%) | 0.60% +0.017 pp | 0.00% +0.000 pp | USD20.83 -3.4% | 8 qtrs — |
| 22 | NORTHERN TRUST CORP | 245.6K +14.4K (+6.2%) | 4.94M +676.4K (+15.9%) | 0.59% +0.034 pp | 0.00% +0.000 pp | USD21.50 -6.4% | 8 qtrs — |
| 23 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 242.8K +242.8K (+100.0%) | 4.89M +4.9M (+100.0%) | 0.58% +0.579 pp | 0.00% +0.001 pp | USD20.12 +0.0% | 5 qtrs — |
| 24 | D. E. SHAW & CO., INC. | 233.3K +233.3K (+100.0%) | 4.69M +4.7M (+100.0%) | 0.56% +0.557 pp | 0.00% +0.003 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 25 | POINT72 ASSET MANAGEMENT, L.P. | 216.7K +216.7K (+100.0%) | 4.36M +4.4M (+100.0%) | 0.52% +0.517 pp | 0.00% +0.005 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 26 | ROSALIND ADVISORS, INC. | 215.9K +215.9K (+100.0%) | 4.34M +4.3M (+100.0%) | 0.52% +0.515 pp | 1.53% +1.527 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 27 | SQUAREPOINT OPS LLC | 186.5K +58.2K (+45.3%) | 3.75M +1.4M (+58.5%) | 0.45% +0.139 pp | 0.00% +0.002 pp | USD21.05 -4.4% | 4 qtrs — |
| 28 | HIDDEN LAKE ASSET MANAGEMENT LP | 152.4K -161.6K (-51.5%) | 3.07M -2.7M (-47.1%) | 0.36% -0.386 pp | 0.78% +0.035 pp | USD22.87 -12.0% | 7 qtrs — |
| 29 | AFFINITY ASSET ADVISORS, LLC | 150.0K +150.0K (+100.0%) | 3.02M +3.0M (+100.0%) | 0.36% +0.358 pp | 0.17% +0.172 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 30 | WOODLINE PARTNERS LP | 147.4K -149.5K (-50.4%) | 2.97M -2.5M (-45.9%) | 0.35% -0.357 pp | 0.01% -0.014 pp | USD19.45 +3.4% | 8 qtrs — |
| 31 | BARCLAYS PLC | 129.2K +87.7K (+211.1%) | 2.60M +1.6M (+166.4%) | 0.31% +0.190 pp | 0.00% +0.000 pp | USD20.88 -3.6% | 8 qtrs — |
| 32 | AMERIPRISE FINANCIAL INC | 118.5K +118.5K (+100.0%) | 2.38M +2.4M (+100.0%) | 0.28% +0.283 pp | 0.00% +0.001 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 33 | JANE STREET GROUP, LLC | 103.3K +103.3K (+100.0%) | 2.08M +2.1M (+100.0%) | 0.25% +0.246 pp | 0.00% +0.000 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 34 | BURKEHILL GLOBAL MANAGEMENT, LP | 100.0K +— (+0.0%) | 2.01M +167.0K (+9.1%) | 0.24% +0.000 pp | 0.13% +0.028 pp | USD18.45 +9.1% | 2 qtrs — |
| 35 | MARSHALL WACE, LLP | 99.0K -81.2K (-45.1%) | 1.99M -1.3M (-40.1%) | 0.24% -0.194 pp | 0.00% -0.002 pp | USD18.45 +9.1% | 6 qtrs — |
| 36 | MORGAN STANLEY | 97.6K -294.4K (-75.1%) | 1.96M -5.3M (-72.9%) | 0.23% -0.703 pp | 0.00% 0.000 pp | USD19.42 +3.6% | 8 qtrs — |
| 37 | WELLINGTON MANAGEMENT GROUP LLP | 82.3K +532.0 (+0.7%) | 1.66M +147.2K (+9.8%) | 0.20% +0.001 pp | 0.00% +0.000 pp | USD22.84 -11.9% | 5 qtrs — |
| 38 | TWO SIGMA INVESTMENTS, LP | 77.5K -14.2K (-15.5%) | 1.56M -133.3K (-7.9%) | 0.18% -0.034 pp | 0.00% 0.000 pp | USD18.45 +9.1% | 4 qtrs — |
| 39 | BANK OF NEW YORK MELLON CORP | 73.1K +9.8K (+15.5%) | 1.47M +303.4K (+26.0%) | 0.17% +0.023 pp | 0.00% +0.000 pp | USD20.89 -3.7% | 8 qtrs — |
| 40 | JPMORGAN CHASE & CO | 69.4K +55.4K (+396.0%) | 1.40M +1.1M (+440.9%) | 0.17% +0.126 pp | 0.00% +0.000 pp | USD20.61 -2.4% | 8 qtrs — |
| 41 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 60.1K +24.0K (+66.4%) | 1.21M +543.1K (+81.5%) | 0.14% +0.057 pp | 0.01% +0.003 pp | USD20.19 -0.3% | 4 qtrs — |
| 42 | MOODY ALDRICH PARTNERS LLC | 56.7K -2.8K (-4.7%) | 1.14M +43.1K (+3.9%) | 0.14% -0.007 pp | 0.21% +0.005 pp | USD21.77 -7.6% | 3 qtrs — |
| 43 | BANK OF AMERICA CORP /DE/ | 56.5K +10.5K (+22.9%) | 1.14M +288.9K (+34.1%) | 0.13% +0.004 pp | 0.00% +0.000 pp | USD21.17 -5.0% | 8 qtrs — |
| 44 | NUVEEN, LLC | 53.6K +6.0K (+12.5%) | 1.08M +199.4K (+22.7%) | 0.13% +0.014 pp | 0.00% +0.000 pp | USD18.88 +6.6% | 4 qtrs — |
| 45 | HRT FINANCIAL LP | 53.4K +53.4K (+100.0%) | 1.07M +1.1M (+100.0%) | 0.13% +0.128 pp | 0.00% +0.003 pp | USD20.12 +0.0% | 3 qtrs — |
| 46 | SG AMERICAS SECURITIES, LLC | 51.4K +14.5K (+39.2%) | 1.04M +353.0K (+51.8%) | 0.12% +0.035 pp | 0.00% -0.001 pp | USD20.40 -1.4% | 6 qtrs — |
| 47 | SIMPLEX TRADING, LLC | 45.6K +38.1K (+511.2%) | 916.6K +779.6K (+569.1%) | 0.11% +0.091 pp | 0.00% +0.000 pp | USD19.85 +1.4% | 2 qtrs — |
| 48 | BALYASNY ASSET MANAGEMENT L.P. | 43.0K +43.0K (+100.0%) | 865.8K +865.8K (+100.0%) | 0.10% +0.103 pp | 0.00% +0.001 pp | USD20.12 +0.0% | 3 qtrs — |
| 49 | SWISS NATIONAL BANK | 40.0K +4.5K (+12.7%) | 804.8K +149.8K (+22.9%) | 0.10% +0.011 pp | 0.00% +0.000 pp | USD24.04 -16.3% | 5 qtrs — |
| 50 | SECTORAL ASSET MANAGEMENT INC | 38.3K -980.0 (-2.5%) | 769.7K +45.8K (+6.3%) | 0.09% -0.002 pp | 0.62% +0.170 pp | USD20.62 -2.4% | 4 qtrs — |
| 51 | TWO SIGMA ADVISERS, LP | 37.1K -6.7K (-15.3%) | 746.5K -61.7K (-7.6%) | 0.09% -0.016 pp | 0.00% 0.000 pp | USD19.63 +2.5% | 4 qtrs — |
| 52 | LOS ANGELES CAPITAL MANAGEMENT LLC | 40.3K +40.3K (+100.0%) | 744.3K +744.3K (+100.0%) | 0.10% +0.096 pp | 0.00% +0.003 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 53 | ANSON FUNDS MANAGEMENT LP | 35.4K -64.5K (-64.6%) | 711.6K -1.1M (-61.4%) | 0.08% -0.154 pp | 0.07% -0.100 pp | USD18.45 +9.1% | 2 qtrs — |
| 54 | ALPS ADVISORS INC | 33.9K +33.9K (+100.0%) | 682.0K +682.0K (+100.0%) | 0.08% +0.081 pp | 0.00% +0.004 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 55 | NEOS INVESTMENT MANAGEMENT LLC | 32.5K +32.5K (+100.0%) | 653.6K +653.6K (+100.0%) | 0.08% +0.078 pp | 0.00% +0.004 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 56 | WELLS FARGO & COMPANY/MN | 32.3K +17.1K (+112.7%) | 649.5K +369.4K (+131.9%) | 0.08% +0.041 pp | 0.00% +0.000 pp | USD21.01 -4.2% | 8 qtrs — |
| 57 | TEMA ETFS LLC | 32.0K +32.0K (+100.0%) | 644.0K +644.0K (+100.0%) | 0.08% +0.076 pp | 0.05% +0.050 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 58 | RHUMBLINE ADVISERS | 31.5K -2.3K (-6.9%) | 632.9K +9.2K (+1.5%) | 0.08% -0.006 pp | 0.00% +0.000 pp | USD21.91 -8.2% | 8 qtrs — |
| 59 | RAFFERTY ASSET MANAGEMENT, LLC | 28.9K -5.5K (-16.0%) | 581.0K -52.9K (-8.3%) | 0.07% -0.013 pp | 0.00% +0.000 pp | USD21.70 -7.3% | 6 qtrs — |
| 60 | ALLIANCEBERNSTEIN L.P. | 28.2K +— (+0.0%) | 567.4K +47.1K (+9.1%) | 0.07% +0.000 pp | 0.00% +0.000 pp | USD23.50 -14.4% | 6 qtrs — |
| 61 | XTX TOPCO LTD | 26.3K +26.3K (+100.0%) | 528.2K +528.2K (+100.0%) | 0.06% +0.063 pp | 0.01% +0.014 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 62 | JUMP FINANCIAL, LLC | 24.2K +3.8K (+18.7%) | 487.3K +110.9K (+29.5%) | 0.06% +0.009 pp | 0.01% +0.002 pp | USD18.71 +7.5% | 2 qtrs — |
| 63 | WALLEYE CAPITAL LLC | 22.1K -5.7K (-20.4%) | 445.0K -67.4K (-13.1%) | 0.05% -0.014 pp | 0.00% -0.001 pp | USD19.58 +2.8% | 3 qtrs — |
| 64 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 21.7K +3.1K (+16.8%) | 436.2K +93.8K (+27.4%) | 0.05% +0.007 pp | 0.00% +0.000 pp | USD23.16 -13.1% | 8 qtrs — |
| 65 | DEUTSCHE BANK AG\ | 21.5K +1.6K (+7.8%) | 433.2K +64.7K (+17.6%) | 0.05% +0.004 pp | 0.00% +0.000 pp | USD23.63 -14.9% | 6 qtrs — |
| 66 | INVESCO LTD. | 16.9K +1.9K (+12.5%) | 339.9K +62.8K (+22.7%) | 0.04% +0.005 pp | 0.00% +0.000 pp | USD25.92 -22.4% | 5 qtrs — |
| 67 | METLIFE INVESTMENT MANAGEMENT, LLC | 16.7K -453.0 (-2.6%) | 335.1K +19.5K (+6.2%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD21.89 -8.1% | 8 qtrs — |
| 68 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 16.6K +16.6K (+100.0%) | 334.7K +334.7K (+100.0%) | 0.04% +0.040 pp | 0.00% +0.004 pp | USD20.12 +0.0% | 3 qtrs — |
| 69 | PRICE T ROWE ASSOCIATES INC /MD/ | 16.1K +1.8K (+12.3%) | 325.0K +60.0K (+22.6%) | 0.04% +0.004 pp | 0.00% +0.000 pp | USD22.08 -8.9% | 6 qtrs — |
| 70 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 15.4K +2.1K (+16.1%) | 310.4K +66.5K (+27.3%) | 0.04% +0.005 pp | 0.00% +0.000 pp | USD21.85 -7.9% | 7 qtrs — |
| 71 | LEGAL & GENERAL GROUP PLC | 15.3K +485.0 (+3.3%) | 307.3K +34.5K (+12.6%) | 0.04% +0.001 pp | 0.00% +0.000 pp | USD25.14 -20.0% | 8 qtrs — |
| 72 | DIMENSIONAL FUND ADVISORS LP | 14.7K +585.0 (+4.1%) | 296.6K +35.4K (+13.6%) | 0.04% +0.001 pp | 0.00% +0.000 pp | USD18.52 +8.6% | 2 qtrs — |
| 73 | QUADRATURE CAPITAL LTD | 12.8K +12.8K (+100.0%) | 256.8K +256.8K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.003 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 74 | AQUATIC CAPITAL MANAGEMENT LLC | 12.3K +12.3K (+100.0%) | 247.6K +247.6K (+100.0%) | 0.03% +0.029 pp | 0.01% +0.007 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 75 | AQR CAPITAL MANAGEMENT LLC | 11.5K -348.0 (-2.9%) | 230.9K +12.7K (+5.8%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD21.77 -7.6% | 6 qtrs — |
| 76 | VIRTU FINANCIAL LLC | 11.3K +11.3K (+100.0%) | 227.0K +227.0K (+100.0%) | 0.03% +0.027 pp | 0.01% +0.009 pp | USD20.12 +0.0% | 3 qtrs — |
| 77 | INTECH INVESTMENT MANAGEMENT LLC | 11.0K +11.0K (+100.0%) | 221.5K +221.5K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.002 pp | USD20.12 +0.0% | 5 qtrs — |
| 78 | UBS ASSET MANAGEMENT AMERICAS INC | 11.0K +45.0 (+0.4%) | 221.5K +19.2K (+9.5%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD21.76 -7.5% | 5 qtrs — |
| 79 | PROFUND ADVISORS LLC | 11.0K +11.0K (+100.0%) | 221.0K +221.0K (+100.0%) | 0.03% +0.026 pp | 0.01% +0.007 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 80 | VIRTUS INVESTMENT ADVISERS, INC. | 10.9K +6.1K (+126.2%) | 219.2K +130.3K (+146.7%) | 0.03% +0.015 pp | 0.06% +0.034 pp | USD19.40 +3.7% | 4 qtrs — |
| 81 | CITIGROUP INC | 8.1K -1.9K (-19.4%) | 162.8K -22.4K (-12.1%) | 0.02% -0.005 pp | 0.00% +0.000 pp | USD24.42 -17.6% | 8 qtrs — |
| 82 | PERSISTENT ASSET PARTNERS LTD | 8.0K +8.0K (+100.0%) | 160.2K +160.2K (+100.0%) | 0.02% +0.019 pp | 0.07% +0.072 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 83 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 7.9K +1.6K (+26.0%) | 158.6K +43.2K (+37.4%) | 0.02% +0.004 pp | 0.00% +0.000 pp | USD25.29 -20.4% | 5 qtrs — |
| 84 | NEW YORK STATE COMMON RETIREMENT FUND | 7.8K +— (+0.0%) | 156.6K +13.0K (+9.1%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD22.33 -9.9% | 7 qtrs — |
| 85 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 6.7K -384.0 (-5.4%) | 135.3K +4.1K (+3.2%) | 0.02% -0.001 pp | 0.01% 0.000 pp | USD26.29 -23.5% | 5 qtrs — |
| 86 | BNP PARIBAS ARBITRAGE, SNC | 5.5K -36.8K (-87.1%) | 110.1K -669.7K (-85.9%) | 0.01% -0.088 pp | 0.00% 0.000 pp | USD18.55 +8.5% | 8 qtrs — |
| 87 | ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | 4.7K +1.5K (+45.6%) | 95.4K +35.3K (+58.8%) | 0.01% +0.004 pp | 0.00% +0.000 pp | USD18.98 +6.0% | 4 qtrs — |
| 88 | KLP KAPITALFORVALTNING AS | 4.3K +1.2K (+38.7%) | 86.5K +29.3K (+51.3%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD24.82 -18.9% | 5 qtrs — |
| 89 | GROUP ONE TRADING, L.P. | 2.9K +2.9K (+100.0%) | 57.4K +57.4K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD20.12 +0.0% | 1 qtrs NEW |
| 90 | QUEST PARTNERS LLC | 2.8K -38.6K (-93.2%) | 56.3K -708.4K (-92.6%) | 0.01% -0.092 pp | 0.00% -0.047 pp | USD18.45 +9.1% | 2 qtrs — |
| 91 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.4K +1.1K (+84.7%) | 47.7K +24.0K (+101.4%) | 0.01% +0.003 pp | 0.00% +0.001 pp | USD21.33 -5.7% | 8 qtrs — |
| 92 | AMERITAS INVESTMENT PARTNERS, INC. | 2.4K +— (+0.0%) | 47.3K +3.9K (+9.1%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD21.72 -7.4% | 8 qtrs — |
| 93 | RUSSELL INVESTMENTS GROUP, LTD. | 2.1K +— (+0.0%) | 41.6K +3.5K (+9.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.48 +8.9% | 3 qtrs — |
| 94 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 2.0K +438.0 (+27.9%) | 40.4K +11.4K (+39.5%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD23.72 -15.2% | 5 qtrs — |
| 95 | US BANCORP \DE\ | 1.1K -176.0 (-13.7%) | 22.4K -1.4K (-5.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD21.20 -5.1% | 5 qtrs — |
| 96 | ROYAL BANK OF CANADA | 981.00 -16.8K (-94.5%) | 21.0K -307.0K (-93.6%) | 0.00% -0.040 pp | 0.00% 0.000 pp | USD18.45 +9.1% | 8 qtrs — |
| 97 | AMALGAMATED BANK | 927.00 -36.0 (-3.7%) | 19.0K +1.0K (+5.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD20.59 -2.3% | 8 qtrs — |
| 98 | GF FUND MANAGEMENT CO. LTD. | 811.00 -62.0 (-7.1%) | 16.3K +210.0 (+1.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD25.10 -19.8% | 5 qtrs — |
| 99 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 807.00 +807.0 (+100.0%) | 16.2K +16.2K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.004 pp | USD20.12 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 88 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Tema Oncology ETF CANC | 1.00% | 1.42M | 0.75% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.80% | 1.71M | 0.50% |
| 3 | Virtus Biotech Clinical Trials ETF BBC | 0.68% | 390.9K | 0.65% |
| 4 | iShares Micro-Cap ETF IWC | 0.29% | 4.28M | 0.60% |
| 5 | Global X - S&P Biotech ETF CURE.AX | 0.27% | 98.6K | 0.45% |
| 6 | State Street SPDR S&P Biotech ETF XBI | 0.27% | 29.74M | 0.35% |
| 7 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.11% | 499.5K | 0.40% |
| 8 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.11% | 80.6K | 0.19% |
| 9 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.11% | 79.0K | 0.35% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.11% | 1.18M | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
5
Sells
0
Shares acquired
1.10M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,100,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-02 | Yao Zhengbin | Director / Officer | A-Award | A | Stock Option (right to buy) | 550,000 | 22.67 | 12.47M | 550,000 | D | ↗ |
| 2026-02-02 | Lutzker Stuart | Director / Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 22.67 | 3.40M | 150,000 | D | ↗ |
| 2026-02-02 | LaChapelle Robin | Officer | A-Award | A | Stock Option (right to buy) | 130,000 | 22.67 | 2.95M | 130,000 | D | ↗ |
| 2026-02-02 | Kung Winston | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 22.67 | 3.17M | 140,000 | D | ↗ |
| 2026-02-02 | Kastenmayer James Paul | Officer | A-Award | A | Stock Option (right to buy) | 130,000 | 22.67 | 2.95M | 130,000 | D | ↗ |
| 2025-12-10 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10% Owner | S-Sale | D | Common Stock | 555,555 | 23.37 | 12.98M | 3,929,117 | I | ↗ |
| 2025-07-11 | LaChapelle Robin | Officer | M-Exempt | A | Common Stock | 2,050 | 2.28 | 4.7K | 126,633 | D | ↗ |
| 2025-06-18 | Peterson Kristine | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 15,502 | 24.89 | 385.8K | 15,502 | D | ↗ |
| 2025-06-18 | Parsey Merdad | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 15,502 | 24.89 | 385.8K | 15,502 | D | ↗ |
| 2025-06-18 | Nolet Chris | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 15,502 | 24.89 | 385.8K | 15,502 | D | ↗ |
| 2025-06-18 | Hohneker John | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 15,502 | 24.89 | 385.8K | 15,502 | D | ↗ |
| 2025-04-28 | Parsey Merdad | Director | A-Award | A | Stock Option (right to buy) | 28,346 | 20.92 | 593.0K | 28,346 | D | ↗ |
| 2024-01-30 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 222,222 | 18.00 | 4.00M | 1,513,664 | — | ↗ |
| 2024-01-30 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10% Owner | P-Purchase | A | Common Stock | 555,555 | 18.00 | 10.00M | 4,484,672 | — | ↗ |
| 2024-01-30 | HEALY JAMES | Director | P-Purchase | A | Common Stock | 444,444 | 18.00 | 8.00M | 1,696,752 | — | ↗ |
| 2024-01-30 | GORDON CARL L | Director / 10% Owner | C-Conversion | D | Series A Preferred Stock | 821,827 | 0.00 | — | 0 | — | ↗ |
| 2024-01-25 | ORBIMED ADVISORS LLC | Director / 10% Owner | — | I | Series B Preferred Stock | 469,615 | 0.00 | — | 0 | — | ↗ |
| 2024-01-25 | Nolet Chris | Director | A-Award | A | Stock Option (right to buy) | 17,884 | 18.00 | 321.9K | 17,884 | — | ↗ |
| 2024-01-25 | Kung Winston | Officer | — | D | Stock Option (right to buy) | 197,238 | 7.76 | 1.53M | 0 | — | ↗ |
| 2024-01-25 | Kastenmayer James Paul | Officer | — | D | Stock Option (right to buy) | 32,873 | 7.76 | 255.1K | 0 | — | ↗ |
| 2024-01-25 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10% Owner | — | I | Series A Preferred Stock | 3,616,041 | 0.00 | — | 0 | — | ↗ |
| 2024-01-25 | HEALY JAMES | Director | — | I | Series B Preferred Stock | 1,252,308 | 0.00 | — | 0 | — | ↗ |
| 2024-01-25 | GORDON CARL L | Director / 10% Owner | — | I | Series A Preferred Stock | 821,827 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
46.37M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Zhengbin (Bing) Yao, Ph.D Chief Executive Officer and President | 596.7K | — | — | 8.41M | 358.0K | 14.0K | 9.37M | 89.67% | ↗ |
| 2 | 2025 | Stuart Lutzker, M.D., Ph.D President, Research and Development | 515.8K | — | — | 2.65M | 247.6K | 14.0K | 3.43M | 77.35% | ↗ |
| 3 | 2025 | Winston Kung, MBA Chief Financial Officer and Treasurer | 492.4K | — | — | 2.65M | 246.3K | 14.0K | 3.41M | 77.91% | ↗ |
| 4 | 2024 | Zhengbin (Bing) Yao, Ph.D Chief Executive Officer and President | 558.2K | — | — | 1.60M | 238.6K | 13.8K | 2.41M | 66.32% | ↗ |
| 5 | 2024 | Winston Kung, MBA Chief Financial Officer and Treasurer | 469.6K | — | — | 1.19M | 158.8K | 13.8K | 1.83M | 64.95% | ↗ |
| 6 | 2024 | Stuart Lutzker, M.D., Ph.D President, Research and Development | 495.9K | — | — | 297.5K | 179.0K | 13.5K | 986.0K | 30.17% | ↗ |
| 7 | 2023 | Zhengbin (Bing) Yao, Ph.D Chief Executive Officer and President | 536.5K | — | — | 394.7K | 241.4K | 13.2K | 1.19M | 33.29% | ↗ |
| 8 | 2023 | Stuart Lutzker, M.D., Ph.D President, Research and Development | 476.9K | — | — | 119.3K | 219.4K | 13.2K | 828.8K | 14.40% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhengbin Yao | Co-Founder, Chairman, President & Chief Executive Officer | 968.7K | — |
| Stuart Lutzker | Co-Founder, President of Research & Development and Director | 777.4K | — |
| Winston Kung | Chief Financial Officer & Treasurer | 752.7K | male |
| Robin LaChapelle | Co-Founder & Chief Operating Officer | 586.5K | female |
| Brent S. Rice | Chief Commercial Officer | — | male |
| Yang Wang | Chief Technology Officer | — | female |
| James Paul Kastenmayer | General Counsel & Secretary | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AVBP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
